Cell and gene therapies are no longer reserved only for ultra-rare diseases. In many therapeutic areas (TAs), advances in viral vector delivery, gene editing technologies, and cell-based medicine are enabling interventions that target disease at its biological source, often through a single administration rather than lifelong treatment.
These developments should be unequivocally positive for patients. However, as gene therapies transition from scientific breakthrough to commercial reality, a more complex picture of access is emerging. Insurance companies that were built to fund chronic, recurring treatments are now being asked to absorb high-cost, one-time therapies with benefits that unfold over years.
The Payer Dilemma: Upfront Costs, Long-Term Value
At the heart of gene therapy adoption lies a structural challenge. Although these therapies are typically delivered just once, their value is realized over a long period of time. Despite their efficacy, many gene therapies are priced between $2 million and $4 million per patient, creating immediate budget pressure for payers. Given the longstanding issue of member churn in the U.S. market, patients may well change insurers before the payer can recognize long-term value.
Payers are also concerned about the durability of these treatments, as long-term outcomes are not fully established at launch. This combination of upfront cost, uncertain durability, and immediate budgetary impact creates a mismatch that traditional reimbursement models were not designed to handle. As gene therapies do not fit neatly into existing access frameworks, payer reactions vary significantly depending on where and how these therapies are being introduced.
This uncertainty is reflected in payer sentiment. According to recent MMIT Indices research, most payers—representing 69% of commercial lives and 92% of Medicare lives—report only moderate satisfaction with currently available gene therapies (3.2 out of 5). At the same time, most payers (representing 55% of commercial lives; 72% of Medicare lives) report a high level of unmet need (3.8 out of 5) in these disease areas, highlighting the gap between the clinical promise of gene therapy and confidence in its long-term value proposition.
Gene Therapy’s Expansion into New Therapeutic Areas
The gene therapy pipeline continues to expand well beyond its origins in ultra-rare disease. Today, there are more than 4,200 gene and cell therapy programs in development, with increasing focus on non-oncology TAs.
This evolution reflects a broader shift from niche, high-cost treatments affecting a few patients to therapies intended for larger patient populations—with potentially system-wide financial implications. Even among currently approved treatments, the diversity of indications—from hemophilia and spinal muscular atrophy (SMA) to diabetes and sickle cell disease—signals how rapidly the field is evolving.
The Durability Question in Hemophilia Gene Therapy
In rare diseases like hemophilia, there is no doubt that gene therapy represents a significant leap forward. However, patients with hemophilia already have access to highly effective treatments, including both factor replacement and non-factor therapies that significantly reduce disease burden but require lifelong administration.
In addition to the issue of cost-efficacy, this creates a fundamentally different payer question about whether gene therapy can realistically replace chronic care. Patients’ durability of response therefore becomes the defining issue. While early results show sustained factor expression, long-term outcomes for patients treated with hemophilia CGTs remain uncertain, as some decline in effect over time has been observed.
In hemophilia, multiple gene therapies targeting similar mechanisms have entered the market with limited comparative data. For payers, this introduces a new challenge: comparing competing “functional cures” without clear long-term differentiation.
Faced with limited utilization, however, several manufacturers have reconsidered their hemophilia gene therapy pipelines and portfolios over the past year. These adjustments include the discontinuation of development, such as Roche’s decision to halt the development of an experimental gene therapy; the cessation of commercialization efforts for FDA-approved therapies, exemplified by Pfizer’s withdrawal of Beqvez; and the termination of strategic partnerships that may impact the progress of promising treatments, as seen in the dissolution of the Pfizer/Sangamo collaboration.
Convenience as a Differentiator in Next-Generation Gene Editing for HAE
In another TA, insights from MMIT’s Message Monitor reveal that not all gene therapies differentiate on efficacy alone. In hereditary angioedema (HAE), a rare genetic disorder, Intelligia Therapeutics is developing an in vivo CRISPR-based gene editing therapy, lonvo-z, which would enable a one-time outpatient administration without the need for extensive preconditioning. Early clinical data demonstrate meaningful reductions in attack frequency, with Phase 2 results showing approximately an 80% decrease in monthly HAE attacks.
However, payer feedback suggests that clinical effectiveness alone may not be the primary driver of adoption in this space. While existing therapies already achieve strong disease control, the key differentiator for gene editing approaches may be convenience, including reduced treatment burden and simplified administration. This introduces a different access dynamic: rather than displacing ineffective care, these therapies must compete against already effective options by offering a superior patient experience.
Access Lessons Learned from Oncology and CAR-T Therapies
In oncology, the story is different. CAR-T therapies have introduced a model that is not only high-cost but also operationally complex. These therapies are patient-specific, delivered in specialized hospital settings and targeted to patients with advanced or refractory disease. Payers have adapted to this complexity relatively quickly, and structured reimbursement pathways, Centers of Excellence, and outcomes-based contracts are now standard components of CAR-T access models.
Importantly, CAR-T is no longer confined to very small populations. In diseases like multiple myeloma, its use is expanding into earlier lines of treatment, increasing the number of eligible patients and raising new concerns around affordability. As a result, oncology has effectively become the testing ground for new gene therapy reimbursement models.
Expanding Access Beyond Specialty Populations
The next wave of gene therapy is moving into TAs with far larger patient populations, including neurology, ophthalmology, and cardiovascular disease. As gene therapy moves into these areas, payers are becoming more concerned about the feasibility of paying for these therapies at scale.
This shift introduces a different type of challenge for payers, as they must contend with more eligible patients, more frequent use, and a greater cumulative budget impact. For example, neurology pipelines in Parkinson’s and ALS are expanding rapidly, and ophthalmology indications such as AMD affect millions of patients. New cardiovascular targets like PCSK9 could apply to broad populations.
Finding Reimbursement Pathways to Support Sustainable Adoption
Rather than limiting access to gene therapies outright, payers are evolving their approaches to manage these risks, beginning with stricter evidence-based utilization management.
Genetic testing is increasingly used as a gatekeeper. While most payers (representing 76% of commercial and 78% of Medicare lives) cover FDA-approved genetic tests and companion diagnostics under their most representative plan, they typically require prior authorization for genetic testing and companion diagnostics. There is also quite a bit of coverage variability for advancements like liquid NGS biomarker testing.
At the same time, contracting models are evolving. Payers are increasingly exploring outcomes-based agreements, value-based pricing models and installment or annuity payments. Perhaps most notably, warranty-based models are gaining attention. In these agreements, manufacturers take on part of the durability risk offering rebates or adjustments if outcomes fall short. Payers are also turning to financial mechanisms like reinsurance and stop-loss coverage to help manage concentrated cost exposure.
As cell and gene therapies scale, the focus will shift from individual access decisions to system-wide sustainability—for both payers and manufacturers. From a pharma perspective, the recent trend of market withdrawals and the strategic reprioritization of several gene therapy programs has highlighted the challenges associated with commercialization, evidence generation, and long-term sustainability. The future of gene therapy may depend as much on innovation in payment models as innovation in biotechnology.
For insights into payer management trends for specific TAs, learn more about MMIT’s Oncology Index and Biologics & Injectables Index. Visit our Message Monitor page for information on tracking payer brand perception, and our Custom Market Research page for tailored insights aligned to your specific business challenges.
